Marie C. Hogan, M.D., Ph.D.

The purpose of ths study is to assess the safety and tolerability of RGLS8429. Addiitionally, to assess the impact of RGLS8429 on ADPKD biomarkers

Other objectives are o assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) and to characterize the pharmacokinetic (PK) properties of RGLS8429 -To assess the impact of RGLS8429 on renal function.

The purpose of this study is to examine patient reported outcomes including pain, quality of life, depression and impact on kidney blood flow before and after procedure to destroy the pain sensory nerves of the kidneys in patients with untreatable one or two sided kidney pain.

The purpose of this trial is to evaluate the effectiveness and safety of 2 treatment regimens of CAM2029 versus placebo in patients with Polycystic Liver Disease (PLD). 

The purpose of this study is to investigate the biological variation in baseline levels of proteins (uELV PC1 and PC2) in individual Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients within a 14 day period that will enable the further optimization of biomarker assays for measuring uELV PC1 and PC2.

The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.

This research study is about developing a rapid, accurate urine test to help diagnose and perhaps monitor ADPKD (Autosomal Dominant Polycystic Kidney Disease).

This Pilot study will enable development & assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).

The purpose of this study is to determine whether the source of urinary CD80 and CD163 and other biomarkers elevated in Nephrotic Syndrome is from renal cells or a subset of circulating white blood cells. Also, the study aims to determine whether CD80 and CD163 and other biomarkers levels can predict disease response to treatment.

The purpose of this study is to develop urine tests that will measure biological markers and use them to track the status of kidney disease. This test may help doctors to better care for patients with kidney disease.

The purpose of this study is to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
 

The purpose of this study is to evaluate and better understand the natural history, clinical characteristics and outcomes of Nephronophthisis, a genetically linked kidney disease that progresses to end stage before the age of 30.

The purpose of this study approach aims to identify exomic alterations that contribute to the development of kidney disease.